Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

May Developmental Experiences Explain "unexplained" Medical Symptoms?
A new theory on the role of developmental experiences is presented in the current issue of Psychotherapy and Psycosomatics.

Peregrine Awarded European Patent For Innovative Labeling Technology Featured In New Study In The Journal Of Nuclear Medicine
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has been awarded a European patent for a novel device and methods for linking biological agents to labels for diagnostic and therapeutic applications. The technology, which is known as In-Line labeling, was developed for the production of radiolabeled anti-cancer antibodies, but is applicable to other agents as well. A study published today in the July 2009 issue of The Journal of Nuclear Medicine confirms that In-Line labeling can dramatically reduce the complexity and cost of producing radiolabeled cancer drugs(1). In-Line labeling is already being used for the production of Peregrine"s radiolabeled antibody Cotara(R), currently in Phase II trials for the treatment of glioblastoma multiforme, a deadly form of brain cancer.
News of the day
Discovery Links Proteins Necessary To Repair Membranes
Researchers at UMDNJ-Robert Wood Johnson Medical School are a step closer to treating, and perhaps preventing, muscle damage caused by disease and aging. In their study, published in the June issue of Journal of Biological Chemistry, the scientists have linked the newly discovered protein MG53 to a pathway that repairs human muscle tissue along with the proteins caveolin-3 (Cav3) and dysferlin. Prior to this study, the underlying interactions that inhibited membrane repair in muscle tissue were unknown. Linking these proteins creates a mechanism that allows damaged membranes to be repaired, which may transform treatment for patients who suffer from severe complications of diseases such as muscular dystrophy, as well as cardiovascular disorders and conditions related to advancing age.
Cardiovascular

Rexahn Achieves 50% Enrollment Milestone In Serdaxin™ Phase IIa Clinical Trial For Depression

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), announced that it has enrolled 50% of the total projected enrollment required for its Phase IIa trial to evaluate the safety and preliminary efficacy of Serdaxin™ as a central nervous system based treatment for Major Depressive Disorder (MDD). The complete trial calls for the enrollment of up to 80 patients at multiple clinical trial sites in the United States. "This patient enrollment milestone in the Serdaxin clinical trial is an exciting step forward. We anticipate that enrollment will continue to move quickly, and preliminary study results may be available by year end. Serdaxin is of particular importance in meeting unmet needs in depression, because it appears to have fast onset of action in animal models and lacks the serious side effects associated with existing antidepressant drugs, including nausea, vomiting, insomnia, weight gain and sexual dysfunction." Said Dr. Chang Ahn, CEO of Rexahn The Serdaxin Phase IIa clinical trial is designed as a randomized, double blind, placebo controlled and dose ranging study. Main endpoints include clinically validated depression rating scales, and quality of life surveys. The Serdaxin Phase IIa study in MDD was initiated February 2009, and the Company anticipates completion of enrollment by July 2009. Rexahn will be presenting at the BIO 2009 International Convention at the Georgia World Congress Center (Room 314, Building A, Level 3) in Atlanta, GA on Wednesday, May 20, 2009 at 3:00 PM ET. About SerdaxinTM SerdaxinTM is a potential market leading CNS neuroprotective agent and antidepressant. Among lead indications, we are investigating Serdaxin for depression in Phase II clinical trials. Serdaxin may achieve greater and broader therapeutic coverage, and appears to have no serious side effects such as nausea, vomiting, insomnia, weight gain, sexual dysfunction, cognitive deficit or motor impairment that are linked to existing antidepressant drugs. Serdaxin has well-established and excellent human safety. In preclinical studies, Serdaxin had onset of action in less than two days. Based on its novel mechanism as a dual serotonin and dopamine enhancer, it is a potential treatment for multiple CNS disorders where these neurotransmitters are depleted or implicated in CNS-based illnesses, such as Parkinson"s disease (PD). Serdaxin has the potential to address both non-motor and motor events of PD by serving as a neuroprotective agent and addressing loss of dopaminergic neurons that lead to loss of control of movements; and further, enhancing serotonin and dopamine levels that are involved in depression and mood disorders. Rexahn has multiple clinical programs planned for Serdaxin including depression and anxiety disorders, Parkinson"s disease, Alzheimer"s and neurodegenerative illnesses, neuroprotection and biodefense uses. Rexahn Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009